X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
anemia - chemically induced (8) 8
female (7) 7
male (7) 7
anemia - drug therapy (6) 6
antineoplastic agents - adverse effects (6) 6
oncology (6) 6
adult (5) 5
aged (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
erythropoietin - administration & dosage (5) 5
erythropoietin - therapeutic use (5) 5
index medicus (5) 5
middle aged (5) 5
anemia (4) 4
cancer (4) 4
epoetin alfa (4) 4
neoplasms - drug therapy (4) 4
anemia - etiology (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
community oncology (3) 3
darbepoetin alfa (3) 3
dose-response relationship, drug (3) 3
double-blind (3) 3
erythropoietin - analogs & derivatives (3) 3
hematinics - therapeutic use (3) 3
hematology (3) 3
hemoglobin (3) 3
nonmyeloid malignancies (3) 3
quality-of-life (3) 3
recombinant proteins (3) 3
risk factors (3) 3
treatment outcome (3) 3
aged, 80 and over (2) 2
anemia - therapy (2) 2
benzamides (2) 2
carcinoma (2) 2
chemotherapy (2) 2
chronic myelogenous leukemia (2) 2
combined modality therapy (2) 2
controlled-trial (2) 2
darbepoetin-alpha (2) 2
drug administration schedule (2) 2
erythropoietin (2) 2
follow-up studies (2) 2
hemoglobins - drug effects (2) 2
hemoglobins - metabolism (2) 2
imatinib (2) 2
imatinib mesylate (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (2) 2
magnetic resonance imaging (2) 2
neoplasms - blood (2) 2
neutropenia - chemically induced (2) 2
neutropenia - therapy (2) 2
paclitaxel - adverse effects (2) 2
phase-iii (2) 2
quality of life (2) 2
randomized trial (2) 2
recombinant-human-erythropoietin (2) 2
retrospective studies (2) 2
surgery (2) 2
survival rate (2) 2
abridged index medicus (1) 1
acinar (1) 1
activating mutation (1) 1
acute myeloid leukemia (1) 1
adenosquamous (1) 1
adolescent (1) 1
anal neoplasms (1) 1
analysis (1) 1
anemia - blood (1) 1
anemic cancer-patients (1) 1
animals (1) 1
antineoplastic agents, phytogenic - adverse effects (1) 1
antineoplastic agents, phytogenic - therapeutic use (1) 1
antiretroviral therapy, highly active (1) 1
antiviral agents (1) 1
anus neoplasms - pathology (1) 1
anus neoplasms - therapy (1) 1
apoe (1) 1
apolipoproteins (1) 1
apolipoproteins e - genetics (1) 1
apolipoproteins e - immunology (1) 1
area under curve (1) 1
area under the curve (1) 1
article (1) 1
bacterial-meningitis (1) 1
biochemistry & molecular biology (1) 1
blast crisis - drug therapy (1) 1
blast crisis - pathology (1) 1
blood transfusion (1) 1
brain-stem response (1) 1
breast cancer (1) 1
cancer-patients (1) 1
candidacy evaluation (1) 1
carboplatin (1) 1
carboplatin - administration & dosage (1) 1
carboplatin - adverse effects (1) 1
carcinoma, squamous cell - pathology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 787 - 798
Journal Article
Diseases of the Colon & Rectum, ISSN 0012-3706, 1/2008, Volume 51, Issue 1, pp. 73 - 81
Journal Article
The Oncologist, ISSN 1083-7159, 05/2006, Volume 11, Issue 5, pp. 536 - 537
Journal Article
Oncologist, ISSN 1083-7159, 05/2006, Volume 11, Issue 5, pp. 536 - 537
Journal Article
Journal Article
Cell, ISSN 0092-8674, 02/2018, Volume 172, Issue 4, pp. 825 - 840.e18
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 3166 - 3166
Abstract Abstract 3166 Background: In ENESTnd, nilotinib (NI) significantly reduced progression and demonstrated superior molecular response rates vs. imatinib... 
Journal Article
Blood, ISSN 0006-4971, 11/2004, Volume 104, Issue 11, pp. 4233 - 4233
Abstract Although pharmacokinetic differences between EPO and DARB are known, clinical comparisons are best determined through randomized clinical trials. This... 
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 21, pp. 1753 - 1753
Abstract Abstract 1753 Background: Ruxolitinib (INC424), a potent and selective oral JAK1 and JAK2 inhibitor, has demonstrated rapid and durable reductions in... 
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 1676 - 1676
Abstract Abstract 1676 Background: Pts treated with nilotinib in the ENESTnd phase 3 trial achieved higher and faster rates of major molecular response (MMR, ≤... 
Journal Article
Journal of the National Comprehensive Cancer Network : JNCCN, ISSN 1540-1405, 2004, Volume 2, pp. S-38 - 41
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 21, pp. 279 - 279
Abstract Abstract 279 Background: COMFORT-II is a randomized, open-label, phase 3 study evaluating the safety and efficacy of ruxolitinib, a potent and... 
Journal Article
Blood, ISSN 0006-4971, 11/2004, Volume 104, Issue 11, pp. 4228 - 4228
Abstract Epoetin alfa (EPO) 40,000–60,000 U SC once weekly (QW) has been shown to increase hemoglobin (Hb) by ~2 g/dL after 8-12 wks in anemic patients (pts)... 
Journal Article
Journal of Supportive Oncology, ISSN 1544-6794, 07/2004, Volume 2, Issue 4, p. 297
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.